dc.contributor.author | Fløtten, Øystein | |
dc.contributor.author | Grønberg, Bjørn Henning | |
dc.contributor.author | Bremnes, Roy M. | |
dc.contributor.author | Amundsen, Tore | |
dc.contributor.author | Sundstrøm, Stein Harald | |
dc.contributor.author | Rolke, Heidi | |
dc.contributor.author | HORNSLIEN, KJERSTI | |
dc.contributor.author | Wentzel-Larsen, Tore | |
dc.contributor.author | Aasebø, Ulf | |
dc.contributor.author | von Plessen, Christian | |
dc.date.accessioned | 2022-11-28T07:48:01Z | |
dc.date.available | 2022-11-28T07:48:01Z | |
dc.date.created | 2012-11-20T13:51:17Z | |
dc.date.issued | 2012 | |
dc.identifier.citation | British Journal of Cancer. 2012, 107 (3), 442-447. | en_US |
dc.identifier.issn | 0007-0920 | |
dc.identifier.uri | https://hdl.handle.net/11250/3034339 | |
dc.description.abstract | Background:
Platinum-based doublet chemotherapy is the standard first-line treatment for advanced non-small cell lung cancer (NSCLC), but earlier studies have suggested that non-platinum combinations are equally effective and better tolerated. We conducted a national, randomised study to compare a non-platinum with a platinum combination.
Methods:
Eligible patients had stage IIIB/IV NSCLC and performance status (PS) 0–2. Patients received up to three cycles of vinorelbine 60 mg m−2 p.o.+gemcitabine 1000 mg m−2 i.v. day 1 and 8 (VG) or vinorelbine 60 mg m−2 p.o. day 1 and 8+carboplatin area under the curve=5 (Calvert's formula) i.v. day 1 (VC). Patients ⩾75 years received 75% of the dose. Endpoints were overall survival, health-related quality of life (HRQoL), toxicity, and the use of radiotherapy.
Results:
We randomised 444 patients from September 2007 to April 2009. The median age was 65 years, 58% were men and 25% had PS 2. Median survival was VG: 6.3 months; VC: 7.0 months, P=0.802. Vinorelbine plus carboplatin patients had more grade III/IV nausea/vomiting (VG: 4%, VC: 12%, P=0.008) and grade IV neutropenia (VG: 7%, VC: 19%, P<0.001). Infections, HRQoL and the use of radiotherapy did not differ significantly between the treatment groups.
Conclusion:
The two regimens yielded similar overall survival. The VG combination had only a slightly better toxicity profile. | |
dc.language.iso | eng | en_US |
dc.rights | Navngivelse-Ikkekommersiell-DelPåSammeVilkår 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/deed.no | * |
dc.title | Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group | en_US |
dc.title.alternative | Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.subject.nsi | VDP::Klinisk farmakologi: 739 | en_US |
dc.subject.nsi | VDP::Clinical pharmacology: 739 | en_US |
dc.subject.nsi | VDP::Klinisk farmakologi: 739 | en_US |
dc.subject.nsi | VDP::Clinical pharmacology: 739 | en_US |
dc.source.pagenumber | 442-447 | en_US |
dc.source.volume | 107 | en_US |
dc.source.journal | British Journal of Cancer | en_US |
dc.source.issue | 3 | en_US |
dc.identifier.doi | 10.1038/bjc.2012.284 | |
dc.identifier.cristin | 963632 | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 2 | |